| x | ANNUAL      REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF      1934 |
|---|------------------------------------------------------------------------------------------------|

| o | TRANSITION      REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF      1934 |
|---|----------------------------------------------------------------------------------------------------|

----

|          |          |                                                                                                                      |   |
|---------------|---------------|---------------------------------------------------------------------------------------------------------------------------|--------|
| Part      I   | Item      1.  | Description      of Business                                                                                              |   |
|          | Item      2.  | Description      of Property                                                                                              |   |
|          | Item      3.  | Legal      Proceedings                                                                                                    |   |
|          | Item      4.  | Submission      of Matters to a Vote of Security Holders                                                                  |   |
|          |          |                                                                                                                      |   |
| Part      II  | Item      5.  | Market      for Common Equity and Related Stockholder Matters                                                             |   |
|          | Item      6.  | Management’s      Discussion and Analysis and Results of Operations and Financial      Condition                    |   |
|          | Item      7.  | Financial      Statements                                                                                                 |   |
|          | Item      8.  | Changes      in and Disagreements with Accountants on Accounting and Financial      Disclosure                            |   |
|          | Item      8A. | Controls      and Procedures                                                                                              |   |
|          | Item      8B. | Other      Information                                                                                                    |   |
|          |          |                                                                                                                      |   |
| Part      III | Item      9.  | Directors,      Executive Officers, Promoters and Control Persons, Compliance with Section      16(a) of the Exchange Act |   |
|          | Item      10. | Executive      Compensation                                                                                               |   |
|          | Item      11. | Security      Ownership of Certain Beneficial Owners and Management                                                       |   |
|          | Item      12. | Certain      Relationships and Related Party Transactions                                                                 |   |
|          | Item      13. | Exhibits                                                                                                                  |   |
|          | Item      14. | Principal      Accountant Fees and Services                                                                               |   |

----

Further, this report contains forward looking statementswithin the meaning of Section 27A of the Securities Act and Section 21E of theSecurities Exchange Act that involve substantial risks anduncertainties.  Such statements include, without limitation, allstatements as to expectation or belief and statements as to the Company’s futureresults of operations, the progress of any research, product development andclinical programs, the need for, and timing of, additional capital and capitalexpenditures, partnering prospects, the protection of and the need foradditional intellectual property rights, effects of regulations, the need foradditional facilities and potential market opportunities.  TheCompany’s actual results may vary materially from those contained in suchforward-looking statements because of risks to which the Company is subject,such as lack of available funding, competition from third parties, intellectualproperty rights of third parties, regulatory constraints, litigation and otherrisks to which the Company is subject.

----

ITEM1.                   DESCRIPTIONOF BUSINESS

| ·  | provide      enough data for statistical proof of safety and  efficacy; |
|--------------|-------------------------------------------------------------------------|
| ·  | compare      the experimental therapy to existing therapies;            |
| ·  | uncover      any unexpected safety problems, such as side-effects;  and |
| ·  | generate      product labeling.                                         |

ITEM2.                   DESCRIPTIONOF PROPERTY

ITEM3.                   LEGALPROCEEDINGS

ITEM4.                      SUBMISSIONOF MATTERS TO A VOTE OF SECURITY HOLDERS

----

ITEM5.                   MARKETFOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS

ITEM6.                   MANAGEMENT’SDISCUSSION AND ANALYSIS AND RESULTS OF OPERATIONS AND FINANCIALCONDITION

----

ITEM7.                   FINANCIALSTATEMENTS

----

|                                                                                                     |   |      |                 |   |   |   |
|----------------------------------------------------------------------------------------------------------|--------|-----------|----------------------|--------|--------|--------|
|                                                                                                     |   | March 31, |                 |
|                                                                                                     |   | 2007      |                 |   | 2006   |   |
|                                                                                                     |   |      |                 |   |   |   |
| ASSETS                                                                                                   |   |      |                 |   |   |   |
|                                                                                                     |   |      |                 |   |   |   |
| Current    assets:                                                                                       |   |      |                 |   |   |   |
|     Cash and      cash equivalents                                                   |   | $         |   --       |   |   | $      | 1,944 |   |
| Totalassets                                                                                              |   | $         |    -- |   |   | $      | 1,944 |   |
|                                                                                                     |   |      |                 |   |   |   |   |   |
| LIABILITIES      AND SHAREHOLDERS' DEFICIT                                                               |   |      |                 |   |   |   |   |   |
|                                                                                                     |   |      |                 |   |   |   |   |   |
| Current      liabilities:                                                                                |   |      |                 |   |   |   |   |   |
|     Accounts      payable and accrued      expenses                                  |   |      | 101,372              |   |   |   | 75,007 |   |
|     Convertible      note payable, net                                               |   |      | 20,914               |   |   |   | -- |   |
|         Total      current      liabilities                      |   |      | 122,286              |   |   |   | 75,007 |   |
| Commitments and      contingencies                                                                       |   |      |                 |   |   |   |   |   |
| Shareholders'      deficit:                                                                              |   |      |                 |   |   |   |   |   |
|     Preferred      stock, no par value, 10,000,000 shares authorized,                |   |      |                 |   |   |   |   |   |
|       no      shares issued or outstanding                                 |   |      | --                   |   |   |   | -- |   |
|     Common      stock, no par value, 500,000,000 shares    authorized,               |   |      |                 |   |   |   |   |   |
|       81,352,500 issued and outstanding at      March 31, 2007 and    2006 |   |      | 1,000                |   |   |   | 1,000 |   |
|     Deficit      accumulated in the development stage                                |   |      | (123,286             | )      |   |   | (74,063 | ) |
|          Total      shareholders’ deficit             |   |      | (122,286             | )      |   |   | (73,063 | ) |
| Total liabilities and      shareholders'      deficit                                                    |   | $         | --                   |   |   | $      | 1,944 |   |

----

|                                                                   |   |              |                 |   |              |   |           | Inception                   |   |
|------------------------------------------------------------------------|--------|-------------------|----------------------|--------|-------------------|--------|----------------|-----------------------------|--------|
|                                                                   |   | Year Ended        |                 |   | Year Ended        |   |           | (February 15, 2005)      to |   |
|                                                                   |   | March 31,    2007 |                 |   | March 31,    2006 |   |           | March 31,    2007           |   |
|                                                                   |   |              |                 |   |              |   |           |                        |   |
| General and administrative      expenses                               |   | $                 | 41,948               |   |              | $      | 72,271         |                        |   | $ | 121,562 |   |
|                                                                   |   |              |                 |   |              |   |           |                        |   |   |   |   |
| Loss from      operations                                              |   |              | (47,499              | )      |              |   | (72,271        | )                           |   | $ | (121,562 | ) |
|                                                                   |   |              |                 |   |              |   |           |                        |   |   |   |   |
| Other income      (expense)                                            |   |              |                 |   |              |   |           |                        |   |   |   |   |
|   Interest      expense                                      |   |              | (1,724               | )      |              |   | --             |                        |   | $ | (1,724 | ) |
|                                                                   |   |              |                 |   |              |   |           |                        |   |   |   |   |
| Net loss                                                               |   | $                 | (49,223              | )      |              | $      | (72,271        | )                           |   | $ | (123,286 | ) |
|                                                                   |   |              |                 |   |              |   |           |                        |   |   |   |   |
| Net loss per      share:                                               |   |              |                 |   |              |   |           |                        |   |   |   |   |
|         Basic      and diluted |   | $                 |    -- |   |              | $      |   -- |                        |   |   |   |   |
|                                                                   |   |              |                 |   |              |   |           |                        |   |   |   |   |
| Weighted average number of common      shares                          |   |              |                 |   |              |   |           |                        |   |   |   |   |
|   outstanding:                                               |   |              |                 |   |              |   |           |                        |   |   |   |   |
|         Basic      and diluted |   |              | 81,352,500           |   |              |   | 81,352,500     |                        |   |   |   |   |

----

|                                                                        |   |   |       |   |   |   |    |         |   |   | Deficit         |   |   |   |     |
|-----------------------------------------------------------------------------|--------|--------|------------|--------|--------|--------|---------|--------------|--------|--------|-----------------|--------|--------|--------|----------|
|                                                                        |   |   |       |   |   |   |    |         |   |   | Accumulated     |   |   |   |     |
|                                                                        |   |   |       |   |   |   |    | Stock        |   |   | During      the |   |   |   |     |
|                                                                        |   |   |       |   |   |   |    | Subscription |   |   | Development     |   |   |   |     |
|                                                                        |   | Shares |       |   | Amount |   |    | Receivable   |   |   | Stage           |   |   | Total  |     |
| Balance      – February 15, 2005    (Inception)   |   |   | 73,000,000 |   |   | $      | 1,000   |         |   | $      | (1,000          | )      |   | $      | --       |   |   | $ | -- |   |
| Recapitalization                                                            |   |   | 8,352,500  |   |   |   | --      |         |   |   | --              |   |   |   | --       |   |   |   | -- |   |
| Net      loss for the year ended   March      31, 2005       |   |   | --         |   |   |   | – |         |   |   | --              |   |   |   | (1,792   | ) |   |   | (1,792 | ) |
| Balance,      March 31, 2005                                                |   |   | 81,352,500 |   |   |   | 1,000   |         |   |   | (1,000          | )      |   |   | (1,792   | ) |   |   | (1,792 | ) |
| Collection      of stock subscription    receivable     |   |   | --         |   |   |   | --      |         |   |   | 1,000           |   |   |   | --       |   |   |   | 1,000 |   |
| Net      loss for the year ended    March      31, 2006 |   |   | --         |   |   |   | – |         |   |   | --              |   |   |   | (72,271  | ) |   |   | (72,271 | ) |
| Balance,      March 31, 2006                                                |   |   | 81,352,500 |   |   | $      | 1,000   |         |   | $      | --              |   |   | $      | (74,063  | ) |   | $ | (73,063 | ) |
| Net      loss for the year ended    March      31, 2007 |   |   | --         |   |   |   | --      |         |   |   | --              |   |   |   | (49,223  | ) |   |   | (49,223 | ) |
| Balance,      March 31, 2007                                                |   |   | 81,352,500 |   |   | $      | 1,000   |         |   | $      | --              |   |   | $      | (123,286 | ) |   | $ | (122,286 | ) |

----

|                                                                                                                           |   |           |     |   |              |   |        | Inception                |   |
|--------------------------------------------------------------------------------------------------------------------------------|--------|----------------|----------|--------|-------------------|--------|-------------|--------------------------|--------|
|                                                                                                                           |   | Year Ended     |     |   | Year Ended        |   |        | (February 15,      2005) |   |
|                                                                                                                           |   | March 31, 2007 |     |   | March 31,    2006 |   |        | to March 31,    2007     |   |
| Cash flows from operating      activities:                                                                                     |   |           |     |   |              |   |        |                     |   |
|     Net      loss                                                                                          |   | $              | (49,223  | )      |              | $      | (72,271     | )                        |   | $ | (123,286 | ) |
|    Adjustments to reconcile net loss      to cash provided    in operating      activities: |   |           |     |   |              |   |        |                     |   |   |   |   |
|         Changes      in assets and liabilities:                                        |   |           |     |   |              |   |        |                     |   |   |   |   |
|         Accounts payable and accrued      liabilities                                  |   |           | 26,365   |   |              |   | 73,215      |                     |   |   | 101,372 |   |
| Net cash provided by operating      activities                                                                                 |   |           | (22,858  | )      |              |   | 944         |                     |   |   | (21,914 | ) |
|                                                                                                                           |   |           |     |   |              |   |        |                     |   |   |   |   |
| Cash flows from investing      activities                                                                                      |   |           | --       |   |              |   | --          |                     |   |   | -- |   |
|                                                                                                                           |   |           |     |   |              |   |        |                     |   |   |   |   |
| Cash flows from financing      activities:                                                                                     |   |           |     |   |              |   |        |                     |   |   |   |   |
|     Collection of stock subscription      receivable                                                       |   |           | --       |   |              |   | 1,000       |                     |   |   | 1,000 |   |
|     Proceeds      from issuance of convertible notes                                                       |   |           | 25,000   |   |              |   | --          |                     |   |   | 25,000 |   |
|      Repayment      of convertible notes payable                                                      |   |           | (4,086   | )      |              |   | --          |                     |   |   | (4,086 | ) |
| Net cash provided by financing      activities                                                                                 |   |           | 20,914   |   |              |   | 1,000       |                     |   |   | 21,914 |   |
|                                                                                                                           |   |           |     |   |              |   |        |                     |   |   |   |   |
| Net increase in      cash                                                                                                      |   |           | 1,944    |   |              |   | 1,944       |                     |   |   | -- |   |
|                                                                                                                           |   |           |     |   |              |   |        |                     |   |   |   |   |
| Cash and cash equivalents,      beginning of period                                                                            |   |           | 1,944    |   |              |   | --          |                     |   |   | -- |   |
| Cash and cash equivalents, end of      period                                                                                  |   | $              | --       |   |              | $      |  1,944 |                     |   | $ |  -- |   |
|                                                                                                                           |   |           |     |   |              |   |        |                     |   |   |   |   |
| Supplemental cash flow      information:                                                                                       |   |           |     |   |              |   |        |                     |   |   |   |   |
|     Cash paid      during the period      for:                                                             |   |           |     |   |              |   |        |                     |   |   |   |   |
|     Interest      expense                                                                                  |   | $              | --       |   |              | $      | --          |                     |   | $ |    -- |   |
|     Incometaxes                                                                                            |   | $              | --       |   |              | $      | --          |                     |   | $ |  -- |   |
|                                                                                                                           |   |           |     |   |              |   |        |                     |   |   |   |   |
|     Cash      received during the period for:                                                              |   |           |     |   |              |   |        |                     |   |   |   |   |
|     Stock      subscription receivable                                                                     |   | $              |  -- |   |              | $      | 1,000       |                     |   | $ | -- |   |

----

| 1.   | ORGANIZATION      AND NATURE OF BUSINESS |
|----------------|------------------------------------------|

| 2.   | GOING      CONCERN |
|----------------|--------------------|

----

| 3.   | SIGNIFICANT      ACCOUNTING POLICIES |
|----------------|--------------------------------------|

| 4.   | COMMON      STOCK |
|----------------|-------------------|

| 5.   | INCOME      TAXES |
|----------------|-------------------|

|                                                         | March      31, 2007                                                                     |
|--------------------------------------------------------------|-----------------------------------------------------------------------------------------|
| Deferred      tax assets attributable to:                    |                                                                                    |
|     Net      operating loss carryforward | $     49,200                                                   |
| Less:  Change      in valuation allowance          | (49,200)                                                                                |
| Net      deferred tax assets                                 | $              -- |

ITEM8.                   CHANGESIN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIALDISCLOSURE

Child Sullivan has notprepared an audit report on Interactive Therapeutics, Inc.

ITEM8A.                      CONTROLSAND PROCEDURES

ITEM8B.                      OTHERINFORMATION

----

ITEM9.                   DIRECTORS,EXECUTIVER OFFICERS, PROMOTERS AND CONTROL PERSONS, COMPLIANCE WITH SECTION16(a) OF THE EXCHANGE ACT

| Name                  |   | Age |   | Position                                                                                           |
|-----------------------|--------|-----|--------|----------------------------------------------------------------------------------------------------|
| J.      Leonard Ivins |   | 71  |   | Chief      Executive Officer, Principal Accounting Officer, Secretary, Treasurer and      Director |
| Brad      Serres      |   | 40  |   | Director                                                                                           |

ITEM10.                      EXECUTIVECOMPENSATION

|  Name and Address of Beneficial      Owner                                                                                    | Number of Shares of Common Stock      Beneficially Owned |  PercentageOf Class  |
|------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------|--------------------------------|
| Beneficial Owners of more than      5%:                                                                                            |                                                     |                           |
|      Silver      Star Holdings Trust (1)                                                                  | 66,430,000                                               | 81.7%                          |
|      Carl      A. Chase (2)                                                                               | 6,570,000                                                | 8.1%                           |
|                                                                                                                               |                                                     |                           |
| Named Executive Officers and      Directors:                                                                                       |                                                     |                           |
|      J.      Leonard Ivins (3)                                                                            | --                                                       | --                             |
|      Brad      Serres (4)                                                                                 | --                                                       | --                             |
|      All      directors & executive officers     as a      group (2 persons) | --                                                       | --                             |

| (1)   | Mr.      Kevan Casey exercises voting and dispositive power of all shares      beneficially owned by Silver Star Holdings Trust.  Mr. Casey’s      business address is 5075 Westheimer, Suite 975, Houston, Texas      77056. |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (2)   | Mr.      Chase’s business address is 5075 Westheimer, Suite 975, Houston, Texas      77056. |
|-----------------|---------------------------------------------------------------------------------------------------|

| (3)   | Mr.      Ivins’ business address is 2036 Brentwood Drive, Houston, Texas      77019. |
|-----------------|--------------------------------------------------------------------------------------------|

| (4)   | Mr.      Serres’ business address is 3602 Vashon Lane, Spring, Texas 77388. Mr.      Serres resigned as a director on March 31,2008. |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------|

----

ITEM13.                      EXHIBITS

| Exhibit      No. | Description                                                                                                                                                                                                                                                                                   |
|------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 3.1              | Articles      of Incorporation (incorporated by reference to Exhibit 3.1 from      Registration Statement on Form-SB filed with the Securities and Exchange      Commission on October 11, 2000)                                                                                              |
| 3.2              | Bylaws      of Tabatha I, Inc. (incorporated by reference to Exhibit 3.2 from      Registration Statement on Form-SB filed with the Securities and Exchange      Commission on October 11, 2000)                                                                                              |
| 4.1              | Specimen      of Stock Certificate (incorporated by reference to Exhibit 4.1 from      Registration Statement on Form-SB filed with the Securities and Exchange      Commission on October 11, 2000)                                                                                          |
| 4.2              | Specimen      Class A Convertible Preferred Stock Certificate (incorporated by reference      to Exhibit 4.2 from Registration Statement on Form-SB filed with the      Securities and Exchange Commission on October 11, 2000)                                                               |
| 14.1             | Code      of Ethics (incorporated by reference to Exhibit 14.1 to Registrant’s Form      10-KSB filed with the Securities and Exchange Commission on June 29,      2005)                                                                                                                |
| 10.1             | Exchange      Agreement between Interactive Therapeutics, Inc. (formerly Tabatha I,      Inc.) and Zigen, Inc. dated February 25, 2005 (incorporated by reference      to Exhibit 10.1 to Registrant’s Form 8-K filed with the Securities and      Exchange Commission of May 31, 2005) |
| 31.1             | Certification      pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act      of 1934, as amended (filed herewith)                                                                                                                                                        |
| 32.1             | Certification      pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of      the Sarbanes-Oxley Act of 2002 (filed herewith)                                                                                                                                             |
|             |                                                                                                                                                                                                                                                                                          |

----

ITEM14.                      PRINCIPALACCOUNTANT FEES AND SERVICES

----

| Signature                                                       | Title                                                                                              | Date                              |
|-----------------------------------------------------------------|----------------------------------------------------------------------------------------------------|-----------------------------------|
| By:  /s/  J. Leonard    Ivins               | Chief      Executive Officer, Principal Accounting Officer, Secretary, Treasurer and      Director |  May       5, 2008 |
|        J.      Leonard Ivins |                                                                                               |                              |
|                                                            |                                                                                               |                              |
| By:  /s/  Brad Serres                       | Director                                                                                           |  May       5, 2008 |
|              Brad Serres     |                                                                                               |                              |

----

| Exhibit      No. | Description                                                                                                                                                                                                                                                                                   |
|------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 3.1              | Articles      of Incorporation (incorporated by reference to Exhibit 3.1 from      Registration Statement on Form-SB filed with the Securities and Exchange      Commission on October 11, 2000)                                                                                              |
| 3.2              | Bylaws      of Tabatha I, Inc. (incorporated by reference to Exhibit 3.2 from      Registration Statement on Form-SB filed with the Securities and Exchange      Commission on October 11, 2000)                                                                                              |
| 4.1              | Specimen      of Stock Certificate (incorporated by reference to Exhibit 4.1 from      Registration Statement on Form-SB filed with the Securities and Exchange      Commission on October 11, 2000)                                                                                          |
| 4.2              | Specimen      Class A Convertible Preferred Stock Certificate (incorporated by reference      to Exhibit 4.2 from Registration Statement on Form-SB filed with the      Securities and Exchange Commission on October 11, 2000)                                                               |
| 14.1             | Code      of Ethics (incorporated by reference to Exhibit 14.1 to Registrant’s Form      10-KSB filed with the Securities and Exchange Commission on June 29,      2005)                                                                                                                |
| 10.1             | Exchange      Agreement between Interactive Therapeutics, Inc. (formerly Tabatha I,      Inc.) and Zigen, Inc. dated February 25, 2005 (incorporated by reference      to Exhibit 10.1 to Registrant’s Form 8-K filed with the Securities and      Exchange Commission of May 31, 2005) |
| 31.1             | Certification      pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act      of 1934, as amended (filed herewith)                                                                                                                                                        |
| 32.1             | Certification      pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of      the Sarbanes-Oxley Act of 2002 (filed herewith)                                                                                                                                             |
|             |                                                                                                                                                                                                                                                                                          |

----

| 1.   | I      have reviewed this annual report on Form 10-KSB of Interactive      Therapeutics, Inc. (the “small businessissuer); |
|----------------|----------------------------------------------------------------------------------------------------------------------------------|

| 2.   | Based      on my knowledge, this report does not contain any untrue statement of a      material fact or omit to state a material fact necessary to make the      statements made, in light of the circumstances under which such statements      were made, not misleading with respect to the period covered by this      report; |
|----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.   | Based      on my knowledge, the financial statements, and other financial information      included in this report, fairly present in all material respects the      financial condition, results of operations and cash flows of the small      business issuer as of, and for, the periods presented in this      report; |
|----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.   | The      small business issuer's other certifying officer(s) and I are responsible      for establishing and maintaining disclosure controls and procedures (as      defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal      control over financial reporting (as defined in Exchange Act Rules      13a-15(f) and 15d-15(f)) for the small business issuer and      have: |
|----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| a.   | Designed      such disclosure controls and procedures, or caused such disclosure      controls and procedures to be designed under our supervision, to ensure      that material information relating to the small business issuer, including      its consolidated subsidiaries, is made known to us by others within those      entities, particularly during the period in which this report is being      prepared; |
|----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| b.   | Designed      such internal control over financial reporting, or caused such internal      control over financial reporting to be designed under our supervision to      provide reasonable assurance regarding the reliability of financial      reporting and the preparation of financial statements for external      purposes in accordance with generally accepted accounting      principles. |
|----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| c.   | Evaluated      the effectiveness of the small business issuer's disclosure controls and      procedures and presented in this report our conclusions about the      effectiveness of the disclosure controls and procedures, as of the end of      the period covered by this report based on such evaluation;      and |
|----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| d.   | Disclosed      in this report any change in the small business issuer's internal control      over financial reporting that occurred during the small business issuer's      fourth fiscal quarter that has materially affected, or is reasonably      likely to materially affect, the small business issuer's internal control      over financial reporting; and |
|----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 5.   | The      small business issuer's other certifying officer(s) and I have disclosed,      based on our most recent evaluation of internal control over financial      reporting, to the small business issuer's auditors and the audit committee      of the small business issuer's board of directors (or persons performing      the equivalent functions): |
|----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| a.   | All      significant deficiencies and material weaknesses in the design or      operation of internal control over financial reporting which are      reasonably likely to adversely affect the small business issuer's ability      to record, process, summarize and report financial information;      and |
|----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| b.   | Any      fraud, whether or not material, that involves management or other      employees who have a significant role in the small business issuer's      internal control over financialreporting. |
|----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 1.   | I      have reviewed this annual report on Form 10-KSB of Interactive      Therapeutics, Inc. (the “small businessissuer); |
|----------------|----------------------------------------------------------------------------------------------------------------------------------|

| 2.   | Based      on my knowledge, this report does not contain any untrue statement of a      material fact or omit to state a material fact necessary to make the      statements made, in light of the circumstances under which such statements      were made, not misleading with respect to the period covered by this      report; |
|----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.   | Based      on my knowledge, the financial statements, and other financial information      included in this report, fairly present in all material respects the      financial condition, results of operations and cash flows of the small      business issuer as of, and for, the periods presented in this      report; |
|----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.   | The      small business issuer's other certifying officer(s) and I are responsible      for establishing and maintaining disclosure controls and procedures (as      defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal      control over financial reporting (as defined in Exchange Act Rules      13a-15(f) and 15d-15(f)) for the small business issuer and      have: |
|----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| a.   | Designed      such disclosure controls and procedures, or caused such disclosure      controls and procedures to be designed under our supervision, to ensure      that material information relating to the small business issuer, including      its consolidated subsidiaries, is made known to us by others within those      entities, particularly during the period in which this report is being      prepared; |
|----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| b.   | Designed      such internal control over financial reporting, or caused such internal      control over financial reporting to be designed under our supervision to      provide reasonable assurance regarding the reliability of financial      reporting and the preparation of financial statements for external      purposes in accordance with generally accepted accounting      principles. |
|----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| c.   | Evaluated      the effectiveness of the small business issuer's disclosure controls and      procedures and presented in this report our conclusions about the      effectiveness of the disclosure controls and procedures, as of the end of      the period covered by this report based on such evaluation;      and |
|----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| d.   | Disclosed      in this report any change in the small business issuer's internal control      over financial reporting that occurred during the small business issuer's      fourth fiscal quarter that has materially affected, or is reasonably      likely to materially affect, the small business issuer's internal control      over financial reporting; and |
|----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 5.   | The      small business issuer's other certifying officer(s) and I have disclosed,      based on our most recent evaluation of internal control over financial      reporting, to the small business issuer's auditors and the audit committee      of the small business issuer's board of directors (or persons performing      the equivalent functions): |
|----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| a.   | All      significant deficiencies and material weaknesses in the design or      operation of internal control over financial reporting which are      reasonably likely to adversely affect the small business issuer's ability      to record, process, summarize and report financial information;      and |
|----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| b.   | Any      fraud, whether or not material, that involves management or other      employees who have a significant role in the small business issuer's      internal control over financialreporting. |
|----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

----